Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Authors
Keywords
Pancreatic ductal adenocarcinoma, Clinical trial, Phase Ib/II, Metastatic, Chemotherapy, Immunotherapy, Copy number instability
Journal
INVESTIGATIONAL NEW DRUGS
Volume 36, Issue 1, Pages 96-102
Publisher
Springer Nature
Online
2017-11-08
DOI
10.1007/s10637-017-0525-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
- (2017) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
- (2017) Gayle S. Jameson et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors
- (2017) Richard A. Skelton et al. JOURNAL OF SURGICAL ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Immune checkpoint therapy for pancreatic cancer
- (2016) Henrik Johansson et al. WORLD JOURNAL OF GASTROENTEROLOGY
- A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis
- (2016) Daniel H. Ahn et al. Therapeutic Advances in Medical Oncology
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
- (2016) Giuseppe V. Masucci et al. Journal for ImmunoTherapy of Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological off-target effects of standard treatments in gastrointestinal cancers
- (2013) A. G. Duffy et al. ANNALS OF ONCOLOGY
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started